Blood donation can detoxify! The world’s first clinical study found that regular blood donation can effectively reduce harmful fluoride in blood that is difficult to remove From JAMA sub issue

The following is the Blood donation can detoxify! The world’s first clinical study found that regular blood donation can effectively reduce harmful fluoride in blood that is difficult to remove From JAMA sub issue recommended by recordtrend.com. And this article belongs to the classification: Life data.

The traditional concept and some negative information about blood donation for a long time have affected people’s enthusiasm for blood donation, resulting in a per capita blood donation rate of only 1% in China, and blood shortages have occurred more or less in blood banks all over the country. At this time, if the odd cake tells you that regular and appropriate blood donation can reduce the harmful chemicals in our blood, I wonder if you will “blood boiling” and want to have a try?

Perfluoroalkyl and polyfluoroalkyl compounds (PFAS) are the general term for a series of synthetic organic fluorides. They are called “permanent chemical substances” because they cannot be degraded in the body. This substance widely exists in non stick cookers, paints, cleaning products, food packaging and fire foam.

More and more studies have shown that high concentrations of PFAS in blood are closely related to various adverse health effects, including impaired immune function, abnormal thyroid function, obesity, liver function changes and so on. In addition, a variety of PFAS are associated with increased cancer risk [1]. However, there is no clinical intervention that can effectively reduce the level of PFAS in blood.

Recently, Dr. Robin Gasiorowski, an Australian scientist, and his team found in a randomized clinical trial, the first in the world, that regular blood donation or plasma donation can significantly reduce the PFAS level in the blood, and plasma donation is more effective. During the 12-month trial period, plasma donation can reduce the serum PFOS concentration by about 30% [2]. This is the first intervention measure that can effectively reduce the level of PFAS in the blood. Relevant research results were published on JAMA network open.

Screenshot of the first page of the thesis

Next, let’s look at how this research was carried out.

This is a 52 week open label, randomized clinical trial. The participants are 285 Victorian fire rescue workers (279 of whom are male, with an average age of 53). The reason for enrollment is that the PFAS level in the blood of firefighters, especially PFOS and perfluorohexylsulfonic acid (pfhxs), is higher than that of the general population [3]. The enrollment condition is that the serum PFOS level is 5ng/ml or above, who are qualified to donate blood, and have not donated blood within 3 months before randomization.

Firefighters with a baseline PFOS level of 5ng/ml or above were randomly assigned to the whole blood donation group (once every 12 weeks for 1 year), the plasma donation group (once every 6 weeks for 1 year) and the observation group (observation only).

The primary end point of the study was the change of serum PFOS and pfhxs levels after 12 months in the plasma donation group or whole blood donation group compared with the baseline and observation groups. Secondary endpoints included changes in 26 other serum pfass from baseline to week 52 and from week 52 to week 64, as well as changes in whole blood cell count, biochemical indicators, thyroid function, and blood lipid levels from screening to week 52.

Participant assignment flowchart

In the whole study, a total of 267 participants (93.7%) completed the whole trial. The participants in the plasma donation group completed an average of 6.4 plasma donations, and the participants in the whole blood donation group completed an average of 4.3 whole blood donations.

First, let’s look at the changes of serum PFOS level.

The results showed that, compared with the baseline level, at the end of the 52 week trial, the serum PFOS level in the plasma donation group decreased by an average of 2.9ng/ml (95%ci:-3.6 to -2.3ng/ml; P <0.001), a decrease of about 30%; The serum PFOS level of the whole blood donation group decreased by an average of 1.1ng/ml (95%ci:-1.5 to -0.7ng/ml; p<0.001), while the serum PFOS level of the observation group at the 52nd week was not significantly different from the baseline level.

Compared with the observation group, the levels of serum PFOS in plasma donation group (-3.1ng/ml, 95%ci:-3.8 to -2.4ng/ml, p<0.001) and whole blood donation group (-1.1ng/ml, 95%ci:-1.7 to -0.5ng/ml, p<0.001) were significantly lower. Among blood donors, the mean serum PFOS level of plasma donation group was 2.0ng/ml lower than that of whole blood donors (95%ci:-2.6 to -1.3ng/ml, p<0.001).

What about the change of serum pfhxs level?

Compared with the baseline level, at the end of the 52 week trial, the average level of pfhxs in the plasma donation group decreased significantly (-1.1 ng/ml, 95%ci:-1.6 to -0.7 ng/ml, p<0.001), but there was no significant difference between the observation group and the whole blood donation group. The average level of pfhxs in the observation group increased by 0.4ng/ml (95%ci:-0.01 to 0.7ng/ml, p=0.06), and that in the whole blood donation group decreased by 0.1ng/ml (95%ci:-0.4 to -0.2ng/ml, p=0.54).

Compared with the observation group, the average level of pfhxs in the plasma donation group (p<0.001) and the whole blood donation group (p=0.001) decreased significantly. The average level of pfhxs in the plasma donation group was 0.9ng/ml lower than that in the whole blood donation group (95%ci:-1.3 to -0.6ng/ml, p<0.001).

Changes in mean levels of PFOS and pfhxs from baseline to 52 weeks

Next, let’s look at the results related to the secondary endpoint.

Secondary endpoints included 26 other pfass, but only PFOA had sufficient data for analysis.

In the plasma donation group, the mean level of PFOA at week 52 was significantly lower (-0.5 ng/ml, 95%ci:-0.7 to -0.3ng/ml, P =0.001). In the whole blood donation group, the mean level of PFOA was not significantly different from the baseline level.

Compared with the observation group, the average level of serum PFOA in the plasma donation group (-0.8ng/ml, 95%ci:-0.9 to -0.6ng/ml, p=0.001) and the whole blood donation group (-0.3ng/ml, 95%ci:-0.4 to -0.1ng/ml, p=0.007) was significantly lower than that at baseline, and the decrease in the plasma donation group was more significant.

Changes in PFOA levels were observed during the follow-up period

The analysis results of other secondary endpoints showed that the hemoglobin level of the whole blood donation group decreased more than that of the plasma donation group (0.51 g/dl, 95%ci:0.72-0.29 g/dl, p=0.001) and the observation group (0.45 g/dl, 95%ci:0.64-0.25 g/dl, p=0.001). No significant differences were observed in the blood lipid level and thyroid, liver or renal function test results among the groups. In terms of safety, the incidence of adverse events in plasma donation group and whole blood donation group were 7.4% and 4.2% respectively.

In general, this world’s first randomized clinical trial showed that for participants with a baseline PFOS level of 5ng/ml or above, regular blood donation or plasma donation could significantly reduce the PFOS level in serum, and plasma donation was more obvious than whole blood donation. This difference may be due to the higher frequency of blood donation (once every 6 weeks) of participants in the plasma donation group, and the level of PFAS in plasma is about twice that of blood PFAS. Plasma donation may more effectively reduce the burden of PFAS on the body.

It is worth mentioning that this is the first randomized clinical trial to systematically quantify whether donated plasma or blood can reduce serum PFAS levels. In view of the difficulty of spontaneous elimination of PFAS, the results of this study may become an effective intervention for people with high PFAS levels. Of course, more studies are needed in the future to evaluate the clinical significance of these findings.

From: singularity.com read more: JAMA netw open: the environment you live in or an important factor in the risk of dementia JAMA: research has found that music can improve health and quality of life. Three consecutive different diets can reduce an average of 11.1 kg. Nature: cancer cells with the same gene group may show different behaviors! According to the 10-year analysis data, 12000 steps per day may reduce the risk of all-cause death by 65%! University of Texas: the study found that sitting for a long time can increase the risk of cancer death by 82%. Journal of the American Medical Association: the global cancer cases have increased by nearly 30% in the past decade. JAMA: research shows that smart phones are hurting users. JAMA: middle-aged obesity is related to so many diseases! JAMA psychiatry: research shows that people with suicidal tendencies are more likely to commit violent crimes. How bad is it for e-cigarette users to smoke cigarettes again? Latest research: the concentration of multiple carcinogens in urine has increased significantly Harvard University: the mortality of elderly patients treated by female doctors is lower than that of patients treated by male doctors CDC: the use of strong drug antibiotics in American hospitals has increased JAMA: the study says that the abuse of antibiotics is worrying people’s Bank of China: questionnaire survey report on urban depositors in the first quarter of 2019

If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.

RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.